VERA
Vera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$35.89
+2.57%Jul 11, 2026, 18:02 UTC
Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy at risk for disease progression.
Source:Jul 9, 2026, 12:00 UTC
Vera Therapeutics announced the appointment of Nancy Boman as Chief Regulatory Officer and the planned retirement of William Turner.
Source:Jul 7, 2026, 16:37 UTC
Vera Therapeutics received FDA accelerated approval for TRUTAKNA for adult patients with primary IgA nephropathy.